{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120"}]}],"title":"Recommended Part 2 Dose 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"150"}]}],"title":"Recommended Part 2 Dose 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"description":"The recommended dose was established by the dose escalation steering committee and based on safety findings during Part 1 of the study.","groups":[{"description":"In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:\n\n* Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)\n* Dose Level 2: 30 μg/kg Day 1 Q3W\n* Dose Level 3: 60 μg/kg Day 1 Q3W\n* Dose Level 4: 90 μg/kg Day 1 Q3W\n* Dose Level 5: 120 μg/kg Day 1 Q3W\n* Dose Level 6: 150 μg/kg Day 1 Q3W\n* Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).","id":"OG000","title":"Part 1: ADCT-402 Dose Escalation"}],"paramType":"NUMBER","populationDescription":"All participants in Part 1 who completed at least one cycle of treatment.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)","title":"Recommended Dose of ADCT-402 for Part 2","type":"PRIMARY","unitOfMeasure":"μg/kg"}